Background: Cardiorenal syndromes (CRS), involving the heart-kidney cross-talk and the activation of neurohumoral and inflammatory pathways, are an entity characterized by high morbidity and mortality.
Objective: To evaluate the prognostic role of risk factors and biomarkers in patients hospitalized for CRS.
Methods: In this observational cohort study, 100 consecutive patients hospitalized for CRS were enrolled. Socio-demographic characteristics, personal medical history, and prior medication use were recorded upon admission, and echocardiography was performed. Moreover, an array of blood markers were measured. The endpoint of interest was a composite of death or dialysis dependence at discharge.
Results: Patients were classified into two groups; Group 1 (N= 52): discharged being dialysis-independent, Group 2 (N=48): death/dialysis dependence at discharge. No significant differences were detected in baseline characteristics between the two groups. Group 2 patients used renin-angiotensin-aldosterone system blockers (RAASb) less often and more frequently presented with oliguria/anuria. Group 2 patients had significantly lower hemoglobin, serum albumin, and 25-hydroxy-vitamin D (25(OH)D). At the same time, serum phosphate, potassium, and parathyroid hormone (PTH) were significantly higher in Group 2 patients. In a multivariate regression analysis, lack of prior RAASb and lower 25(OH)D levels were independently associated with an increased risk of death or dialysis dependence at discharge. 25(OH)D/PTH ratio was the most accurate predictor of the composite endpoint (Sensitivity: 79.4%, Specificity: 70.4%).
Conclusion: Lack of prior RAASb use, high PTH, low 25(OH)D levels, and low 25(OH) D/PTH ratio are associated with a poor prognosis in patients hospitalized for CRS.
[http://dx.doi.org/10.1159/000442300] [PMID: 26989397]
[http://dx.doi.org/10.1093/eurjhf/hfq077] [PMID: 20484366]
[http://dx.doi.org/10.1111/j.1523-1755.2004.00657.x] [PMID: 15149351]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.028814] [PMID: 30354446]
[http://dx.doi.org/10.1016/j.atherosclerosis.2020.07.027] [PMID: 32858395]
[http://dx.doi.org/10.3390/ijms22126607] [PMID: 34205487]
[http://dx.doi.org/10.1161/CIR.0000000000000664] [PMID: 30852913]
[http://dx.doi.org/10.1093/eurheartj/ehp507] [PMID: 20037146]
[http://dx.doi.org/10.1136/bmj.39335.541782.AD] [PMID: 17947786]
[http://dx.doi.org/10.1056/NEJMoa2102953] [PMID: 34554658]
[http://dx.doi.org/10.1093/eurheartj/ehab368] [PMID: 34447992]
[http://dx.doi.org/10.1016/j.echo.2014.10.003] [PMID: 25559473]
[http://dx.doi.org/10.1016/j.echo.2016.01.011] [PMID: 27037982]
[http://dx.doi.org/10.1530/ERP-17-0071] [PMID: 30012832]
[http://dx.doi.org/10.1016/j.echo.2017.01.007] [PMID: 28314623]
[http://dx.doi.org/10.1016/j.echo.2014.09.009] [PMID: 25559474]
[http://dx.doi.org/10.1016/j.compbiomed.2021.104320] [PMID: 33735760]
[http://dx.doi.org/10.1016/j.cardfail.2014.12.012] [PMID: 25573829]
[http://dx.doi.org/10.3109/0886022X.2012.717478] [PMID: 22950572]
[http://dx.doi.org/10.1093/ckj/sfab029] [PMID: 34804520]
[http://dx.doi.org/10.1001/jamainternmed.2020.0193] [PMID: 32150237]
[http://dx.doi.org/10.2174/1570161119666211119142746] [PMID: 34802405]
[http://dx.doi.org/10.1016/j.medine.2017.07.002] [PMID: 28847615]
[http://dx.doi.org/10.1210/jc.2017-00105] [PMID: 28453636]
[http://dx.doi.org/10.1007/s00394-018-1806-y] [PMID: 30121806]
[http://dx.doi.org/10.3390/nu13020335] [PMID: 33498709]
[http://dx.doi.org/10.1016/j.ijcard.2016.09.014] [PMID: 27657477]
[http://dx.doi.org/10.1038/ejcn.2017.59] [PMID: 28488689]
[http://dx.doi.org/10.1210/jc.2013-1333] [PMID: 23666975]
[http://dx.doi.org/10.1016/j.nut.2018.10.028] [PMID: 30703569]